SCHEMBL2382287

SCHEMBL2382287

Oc1cc(Br)ccc1C1CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.43
WDR5 P61964 3/20 0.39
HTR2A P28223 3/20 0.38
HTR2C P28335 3/20 0.38
CES2 O00748 1/20 0.38
GALR3 O60755 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTGDR Q13258 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
ERN1 O75460 1/20 0.36
KDM1A O60341 4/20 0.36
KDM1B Q8NB78 1/20 0.36
HTR2B P41595 2/20 0.36
BCL2 P10415 1/20 0.35
MCL1 Q07820 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30809664 1.00 ALOX15 (0.43) ALOX15WDR5HTR2AHTR2CCES2
SCHEMBL931388 0.83 ALOX15 (0.48) ALOX15WDR5HTR2AHTR2CCES2
SCHEMBL12954655 0.80 HTR2A (0.44) HTR2AHTR2CHTR2B
SCHEMBL16905177 0.79 PTGDR (0.40) HTR2AHTR2CCYP1A2PTGDRPTGDR2
SCHEMBL17376741 0.79 CES2 (0.37) ALOX15WDR5HTR2AHTR2CCES2
SCHEMBL19249421 0.77 TYR (0.48) CES2CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL4961987 0.76 QDPR (0.53) WDR5CYP2C9KDM4E
SCHEMBL15600247 0.75 NUDT1 (0.47) ALOX15WDR5HTR2AHTR2CCES2
SCHEMBL959572 0.75 NUDT1 (0.51) ALOX15WDR5CES2GALR3CYP1A2
SCHEMBL402737 0.74 KDM1A (0.42) HTR2AHTR2CPTGDRPTGDR2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561976-A2 UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS Vandria SA (CH) 2025-06-04 EP disclosed
CN-119948002-A Urolithin derivatives and therapeutic use 范徳利亚股份公司 2025-05-06 CN disclosed
US-20240051933-A1 UROLITHIN DERIVATIVES AND THERAPEUTIC USES VANDRIA SA (CH) 2024-02-15 US disclosed
WO-2024023585-A2 UROLITHIN DERIVATIVES AND THERAPEUTIC USES VANDRIA SA (CH) 2024-02-01 WO disclosed
WO-2024023585-A2 UROLITHIN DERIVATIVES AND THERAPEUTIC USES VANDRIA SA (CH) 2024-02-01 WO disclosed
EP-3924343-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS Merck Sharp & Dohme Corp. (US) 2021-12-22 EP disclosed
EP-2362731-B1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2016-04-06 EP disclosed
EP-2362731-B1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2016-04-06 EP disclosed
EP-2348857-B1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2016-02-24 EP disclosed
EP-2348857-B1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2016-02-24 EP disclosed
US-20110218174-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2011-09-08 US disclosed
US-20110218174-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2011-09-08 US disclosed
WO-2010051206-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed
WO-2010047982-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-29 WO disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 US disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 US disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 US disclosed
WO-2010036613-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-01 WO disclosed
WO-2010036613-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-01 WO disclosed
US-4663340-A RESPIRATORY SYSTEM DISORDERS NAJER HENRY (FR) 1987-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 ALOX15 3005/4885WDR5 489/4885HTR2A 3633/4885
US-20240051933-A1 UROLITHIN DERIVATIVES AND THERAPEUTIC USES AIFM2, GPX1, TXN2 ALOX15 63/4885WDR5 3187/4885HTR2A 3640/4885
US-20110218174-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 ALOX15 3005/4885WDR5 489/4885HTR2A 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.